One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?.
doi : 10.1200/JCO-25-01932
Volume 43(34) pgs. 3631-3689 December 1, 2025
Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer.
doi : 10.1200/JCO-25-01630
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
doi : 10.1200/JCO-25-00809
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
doi : 10.1200/JCO-25-00582
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
doi : 10.1200/JCO-25-01693
Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy.
doi : 10.1200/JCO-25-02283
Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
doi : 10.1200/JCO-25-01656
Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
doi : 10.1200/JCO-25-01879
